Welcome to our dedicated page for Acurx Pharmaceuticals SEC filings (Ticker: ACXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Acurx Pharmaceuticals, Inc. (ACXP) SEC filings page on Stock Titan aggregates the company’s regulatory documents from the U.S. Securities and Exchange Commission, giving investors a structured way to review its disclosures as a late-stage biopharmaceutical developer of Gram-positive selective DNA polymerase IIIC (pol IIIC) inhibitor antibiotics.
Through this page, users can access registration statements such as Acurx’s Form S-1 filings, which describe the company’s business overview, risk factors, emerging growth company status, and details of financing arrangements including equity lines of credit and warrant inducement transactions. These documents explain how Acurx raises capital to fund its ibezapolstat Phase 3 program and broader DNA pol IIIC pipeline.
Investors can also review current reports on Form 8-K that Acurx files to report material events. Recent 8-K filings describe actions such as a 1-for-20 reverse stock split, amendments to the certificate of incorporation to increase authorized shares, warrant agreements, and Nasdaq compliance developments. These filings provide formal documentation of corporate actions that affect ACXP’s capital structure and listing status.
Proxy materials, including definitive proxy statements (DEF 14A), outline matters submitted to stockholders, such as approval of warrant-related share issuances and authorized share increases. Together with interim and annual financial statements referenced in Acurx’s reports, these filings give insight into operating expenses, research and development spending, and shareholders’ equity for a company advancing late-stage antibiotic candidates.
On Stock Titan, ACXP filings are paired with AI-powered summaries that highlight key points—such as how a reverse stock split changes share counts, or how a new S-1 relates to existing financing agreements—so readers can more quickly interpret lengthy documents while retaining the option to drill down into the full SEC text.
Acurx Pharmaceuticals, Inc. is registering 1,300,000 shares of common stock for resale by Lincoln Park Capital under an existing equity purchase agreement. These shares relate to an up to $12.0 million equity line, of which $7.3 million has already been drawn through sales of 1,835,000 shares.
Acurx will not receive proceeds from Lincoln Park’s resales, but may receive up to an additional $4.7 million from future share sales to Lincoln Park at its discretion. As of April 20, 2026, 4,278,492 shares were outstanding; if all 1,300,000 shares were issued, they would represent about 23% of outstanding stock. The prospectus highlights dilution and stock price pressure risks, alongside recent financing of approximately $2.5 million in an April 2026 registered direct offering and progress on its ibezapolstat program for recurrent C. difficile infection.
Acurx Pharmaceuticals, Inc. is filing an S-1 to register the resale of up to 1,650,170 shares of common stock issuable upon exercise of Series H warrants with a $2.78 per share exercise price. Only selling stockholders will receive resale proceeds; Acurx would receive up to about $4.6 million if all warrants are exercised for cash. These Series H warrants were issued in an April 2026 private placement tied to a concurrent $2.5 million registered direct offering. Acurx is a late-stage biopharmaceutical company developing Gram-positive targeted antibiotics and its stock trades on Nasdaq under the symbol ACXP.
Acurx Pharmaceuticals director Carl Sailer received a stock option grant tied to his service on the company’s board. The award covers 2,150 options for Common Stock at an exercise price of $2.36 per share.
The options were granted as part of Acurx’s Director Compensation Policy and will fully vest on April 20, 2027. Following this award, Sailer holds stock options for 2,150 underlying shares, which are scheduled to expire on April 20, 2036.
Acurx Pharmaceuticals director Jack H. Dean received a compensatory stock option award for service on the company’s board. The grant covers 2,150 shares of common stock at an exercise price of $2.36 per share, expiring on April 20, 2036.
The option was granted at no cost and is scheduled to vest in full on April 20, 2027 under Acurx’s Director Compensation Policy. This Form 4 reports an option grant only; it does not show any open‑market purchases or sales of Acurx common stock by the director.
Acurx Pharmaceuticals director James J. Donohue received a stock option grant covering 2,150 shares of common stock as board compensation. The option has an exercise price of $2.36 per share, vests on April 20, 2027, and expires on April 20, 2036. Following the grant, he holds 2,150 stock options directly.
Acurx Pharmaceuticals, Inc. director Thomas L. Harrison received a stock option award as compensation for service on the company’s board of directors. The grant covers 2,150 stock options for common stock at an exercise price of $2.36 per share.
The options were awarded at no upfront cost and will vest on April 20, 2027, meaning they become exercisable on that date. The options are scheduled to expire on April 20, 2036 if not exercised. Following this grant, Harrison holds stock options covering 2,150 shares directly.
Acurx Pharmaceuticals, Inc. director Joseph C. Scodari received a stock option grant related to his service on the company’s board. The award covers 2,150 stock options for common stock at an exercise price of $2.36 per share, with all options vesting on April 20, 2027.
The options expire on April 20, 2036. After this grant, Scodari holds 2,150 stock options directly, reflecting a compensation-related award rather than an open‑market share purchase or sale.
Acurx Pharmaceuticals director Robert J. DeLuccia received a compensation grant of stock options covering 37,100 shares of common stock. The options were granted on April 20, 2026 with an exercise price of $2.36 per share and expire on April 20, 2036.
The options vest in 36 equal monthly installments starting on the grant date, meaning the award vests gradually over three years. Following this grant, DeLuccia holds stock options for 37,100 underlying shares directly, with no additional derivative positions shown in this filing.
Acurx Pharmaceuticals, Inc. reported that President and CEO David P. Luci received a grant of stock options. On April 20, 2026, he was granted options to purchase 37,100 shares of common stock at an exercise price of $2.36 per share.
The options vest in 36 equal monthly installments starting on the grant date and expire on April 20, 2036. Following this grant, he holds 37,100 stock options directly, each tied to one underlying share of Acurx common stock.
Acurx Pharmaceuticals, Inc. reported that its Chief Financial Officer, Robert G. Shawah, received a grant of stock options covering 25,900 shares of common stock on April 20, 2026.
The options have an exercise price of $2.36 per share, expire on April 20, 2036, and vest in 36 equal monthly installments starting on the grant date. After this grant, he holds stock options for 25,900 shares directly as reported in this filing. This is a compensation-related award rather than an open-market share purchase or sale.